Not yet recruitingInterventionalPhase 2Last updated Aug 14, 2026

A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis

A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HS-20118 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Overview

ClinicalTrials.gov ID: NCT07765628
Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY
Brief Summary: The primary objective of this study is to evaluate the efficacy of HS-20118 compared with placebo in participants with moderate to severe plaque psoriasis.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Aug 6, 2026Estimated
Primary Completion Date: Feb 28, 2027Estimated
Completion Date: Jul 10, 2027Estimated

Study Record Dates

First Submitted: Aug 11, 2026
First Submitted that Met QC Criteria: Aug 11, 2026
First Posted: Aug 14, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 11, 2026
Last Update Posted: Aug 14, 2026Actual
Last Verified: Aug 2026

NCT06077331Unknown status

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

NCT06926582Not yet recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis

NCT06844799Not yet recruiting

A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis

NCT06672393Not yet recruiting

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

NCT06846710Recruiting

Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

NCT07158268Not yet recruiting

A Phase 2 Study of HSK47388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate-to-Severe Plaque Psoriasis